Humavant™ RTF (Fortified Human Milk)

The only 100% human milk-based fortified human milk for use when mother’s own milk is not available.

  • Provides an easy, convenient, labor saving way to deliver an exclusive human milk-based diet when mother’s own milk is unavailable.
  • Easy to use, just thaw and feed; eliminates mixing errors and saves time.
  • Once the thawing process begins, administer within 48 hours.
  • Product standardization ensures consistent and predictable delivery of nutrients available in 82, 89, and 97 kcal/100 mL.
Clinical trials shows the use of Humavant RTF resulted in fewer days on TPN and no cases NEC for VLBW
 

This multicenter, randomized, controlled trial compared an exclusive human milk diet vs preterm formula in extremely premature infants. There was a significant difference in median parenteral nutrition days (27 vs 36), in Humavant™ HMF vs preterm formula groups, respectively (p=.04), and surgical NEC was significantly fewer (0 cases vs 4 cases) with Humavant™ HMF vs preterm formula, (p=.04).1

*This study followed a 2009 publication (Sullivan et al.) which demonstrated significantly fewer surgical NEC cases while receiving an EHMD, including Humavant HMF, when compared with infants receiving cow milk-based fortifier or, when mother’s own milk was unavailable, preterm formula.2



This retrospective cohort study included data from infants at four hospitals representing different regions of the U.S. during four different time periods between 2006 and 2013. 
 

An exclusive human milk diet shows statistically significant reduction in late-onset sepsis, retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and patent ductus arteriosus (PDA), as well as a decrease in number of ventilator days.3

This chart is based on an article reporting the results of a large, multicenter, retrospective cohort study (1,587 patients) comparing the outcomes of extremely premature infants (birth weight <1,250 g) who received a diet including cow milk-based products (BOV) versus infants who received an exclusive human milk-based diet (HUM).3

  • The primary outcomes, NEC and mortality, were statistically significant. The BOV group mortality rate was 17.2% (132/768), and the HUM group rate was 13.6% (111/819; p=0.04).
  • For every 10 infants, one case of NEC was prevented with an exclusive HUM diet.
  • Reduction of ventilator days from a mean of 32 days with a median of 17 days to a mean of 29 days with a median of 9 days (p=0.003).


Greater morbidity in extremely preterm infants fed a diet containing cow milk-based protein products.

A combined analysis of two randomized clinical studies demonstrates a dose-response relationship that negatively affects patient outcomes. For every 10% increase in the volume of milk containing cow milk, the risk of NEC increases by 11.8%, surgical NEC by 20.6%, and sepsis by 17.9%.4*